AUSTIN, Texas -- Hepatorenal syndrome (HRS) type 1 patients showed clinically meaningful responses to terlipressin (Terlivaz) under an alternative definition of treatment success, according to a ...

In this exclusive video, Andrew Allegretti, MD, MSc, discusses his poster from The Liver Meeting Digital Experience that explored factors associated with response to terlipressin treatment in patients ...

Credit: Getty Images. The Company is currently evaluating OCE-205 in a phase 2 trial in adults who have developed hepatorenal syndrome with acute kidney injury. The Food and Drug Administration (FDA) ...

The US Food and Drug Administration's (FDA's) Cardiovascular and Renal Drugs Advisory Committee narrowly recommended, by an 8-7 vote, that the agency grant marketing approval to terlipressin for the ...

Please provide your email address to receive an email when new articles are posted on . In this exclusive video, Andrew Allegretti, MD, MSc, from Massachusetts General Hospital, discusses his poster ...

-Post-hoc analyses showcase Mallinckrodt's commitment to patients with HRS involving rapid reduction in kidney function,1an acute and life-threatening condition2- Terlipressin is an investigational ...

Mallinckrodt plc, a global specialty pharmaceutical company, today announced that the Company supports the inaugural Hepatorenal Syndrome (HRS) Awareness Day, established by the American Liver ...

Credit: Getty Images. Terlivaz is a vasopressin analogue selective for V1 receptors. The Food and Drug Administration (FDA) has approved Terlivaz ® (terlipressin) injection to improve kidney function ...

The US Food and Drug Administration (FDA) has approved terlipressin (Terlivaz), the first and only drug approved for patients with hepatorenal syndrome (HRS). HRS is characterized by progressive ...

DUBLIN, Nov. 16, 2020 /PRNewswire/ -- Mallinckrodt plc, a global biopharmaceutical company, today announced findings from a large U.S. database review of patient profiles and outcomes of patients ...

Financing from RA Capital Management, Venrock and Vivo Capital will enable the biopharmaceutical company to advance OCE-205 for treatment of hepatorenal syndrome Phase 2 clinical trial to initiate in ...